Who We Are
We are passionate about improving diagnostic accuracy.
Accurate and precise diagnosis is crucial for optimal management of patients with cancer. Our vision is to help create a world in which all cancer patients are treated appropriately and as individuals, by providing innovative solutions for precision molecular diagnostics.
Our team reflects the interdisciplinary collaboration required to solve this challenge in oncology, from statistics and data science to genetics, pathology and healthcare.
What We Do
We combine world-leading scientific and medical expertise with cutting-edge technical innovation.
The company has developed its expertise since its establishment in 2022, building on decades of combined experience of its founders. We conduct research and development, certification and marketing of software solutions for molecular tumour classification based on DNA methylation profiling and machine learning. Find out about our breakthrough technology here.
Latest news
A national framework with the NHS Genomic Medicine Service brings methylation-based CNS tumour classification to genomic laboratory services across England, free of charge for all paediatric patients for three years.
Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.
A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.
